Court Proceeding on Alleged Smuggling of Over 95,000 E-cigarettes by Former Taipei Customs

Regulations by 2FIRSTS.ai
May.23.2024
Court Proceeding on Alleged Smuggling of Over 95,000 E-cigarettes by Former Taipei Customs
Former Taipei Customs officer Huang, accused of aiding smuggling over 95,000 IQOS e-cigarettes, denied charges in court.

According to a report from the United News Network of Taiwan on May 23, Huang, a former pre-inspection officer at the Zhubei Branch of the Taipei Customs Office, is accused of leaking the scheduling of X-ray machine inspections to freight and customs brokers, assisting in smuggling over 95,000 IQOS e-cigarettes. This case is currently undergoing its first court preparatory procedure at the Taoyuan District Court.

 

Huang and a delivery worker surnamed Yan denied involvement in the case, while the other 12 freight and customs brokers admitted guilt and requested leniency from the court. The judge, after conducting an investigation, stated that further preparations for the trial will take place on the afternoon of July 10th.

 

Huang denied the prosecutors' allegations that he assisted in the smuggling of goods by 5 freight forwarders, stating that he did not provide schedules to anyone and did not receive requests from 12 other freight and customs industry professionals. He also claimed to have no knowledge of the smuggled goods being e-cigarettes. In addition, Yan denied the allegations and his defense lawyer argued that IQOS e-cigarettes are not listed as regulated products under the amended Tobacco and Alcohol Administration Law, therefore requesting clarification on whether e-cigarettes are considered private tobacco under the law and requesting the summoning of other industry professionals to testify in court.

 

The Taiwan Customs Administration discovered a large number of unreported e-cigarettes successfully cleared customs in October 2022. The agency deemed the situation to be serious and requested mutual inspections by the customs and inspection departments. Upon reviewing enforcement images, the agency found that a significant number of e-cigarettes had indeed passed through the X-ray machines, and all were cleared during the shift of employee Huang. As a result, the Customs Administration suspects Huang of potentially allowing private e-cigarettes to clear customs without authorization.

 

Further investigation revealed that Mr. Huang did not open and inspect the package after learning that e-cigarettes are regulated products. He allegedly provided the inspection schedule to customs brokers in order to profit from companies such as Dongqing, Fanxi, Xihe, Huigao, and e-cigarette suppliers. He then used misleading names such as cushion, stationery, and storage rack to declare the goods, allowing the e-cigarettes to pass through customs.

 

It is reported that during Huang's term of office from September to October 2022, an estimated 74,000 e-cigarettes are expected to enter the market. Due to Huang's denial of the charges and the large quantity of e-cigarettes involved, the prosecution has requested the court to impose a heavy sentence.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
British e-liquid manufacturer Riot Labs has introduced a fictional “candidate” called Riot Man around the Clacton parliamentary by-election, seeking to mobilize consumers and retailers against parts of the UK government’s proposed restrictions on vape packaging, device appearance and retail displays. Riot Man is not listed as an official candidate.
Aug.12
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24